FDA approves once-daily MIRAPEX ER for the treatment of early Parkinson’s disease.

Boehringer Ingelheim Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson’s disease (PD).  Click here to read the press release.